Β-blocker therapy and heart rate control during exercise testing in the general population: role of a common G-protein β-3 subunit variant. (September 2010)
- Record Type:
- Journal Article
- Title:
- Β-blocker therapy and heart rate control during exercise testing in the general population: role of a common G-protein β-3 subunit variant. (September 2010)
- Main Title:
- Β-blocker therapy and heart rate control during exercise testing in the general population: role of a common G-protein β-3 subunit variant
- Authors:
- Dörr, Marcus
Schmidt, Carsten O
Spielhagen, Thomas
Bornhorst, Alexa
Hentschel, Katharina
Franz, Christina
Empen, Klaus
Kocher, Thomas
Diehl, Scott R
Kroemer, Heyo K
Völzke, Henry
Ewert, Ralf
Felix, Stephan B
Rosskopf, Dieter - Abstract:
- Aim: Impaired heart rate (HR) response to exercise is associated with increased cardiovascular morbidity and mortality. We analyzed whether common variants (rs5443/C825T and rs5442/G814A) in the G-protein β3 subunit ( GNB3 ) gene modulate interindividual variation in β-blocker responses with respect to HR.Materials & methods: Among 1614 subjects (347 current β-blocker users) of a population-based study, HR during symptom-limited exercise testing was analyzed by multilevel linear regression models adjusted for potential confounders.Results: In β-blocker users, but not in nonusers, HR was attenuated in rs5443 T allele carriers (TC/TT vs CC) with lower adjusted HR over the entire exercise period from rest to peak workload (3.5 bpm; 95% CI: 1.1–5.8; p < 0.01), and during recovery (4.2 bpm; 95% CI: 0.6–7.8; p = 0.02). The genotype-related HR reducing effect at peak exercise varied by up to 7.5 bpm (CC vs TT), more than a third (35.9%) of the total β-blocker effect (20.9 bpm). By contrast, rs5442 had no impact on any HR-related parameter.Conclusion: In this population-based sample, a common GNB3 polymorphism (C825T) was significantly related with response to β-blocker therapy with respect to HR during exercise and HR recovery, respectively. Further prospective studies are needed to confirm these associations and to examine their potential clinical relevance.
- Is Part Of:
- Pharmacogenomics. Volume 11:Number 9(2010)
- Journal:
- Pharmacogenomics
- Issue:
- Volume 11:Number 9(2010)
- Issue Display:
- Volume 11, Issue 9 (2010)
- Year:
- 2010
- Volume:
- 11
- Issue:
- 9
- Issue Sort Value:
- 2010-0011-0009-0000
- Page Start:
- 1209
- Page End:
- 1221
- Publication Date:
- 2010-09
- Subjects:
- β-blocker -- epidemiology -- exercise testing -- genetic susceptibility -- GNB3 -- heart rate -- polymorphism
Pharmacogenomics -- Periodicals
615.1 - Journal URLs:
- http://www.futuremedicine.com/loi/pgs ↗
http://www.futuremedicine.com/ ↗ - DOI:
- 10.2217/pgs.10.88 ↗
- Languages:
- English
- ISSNs:
- 1462-2416
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6446.249500
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 15314.xml